PMID- 35117707
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 9
IP  - 5
DP  - 2020 May
TI  - Tumor-derived exosomes facilitate tumor cells escape from drug therapy in clear 
      cell renal cell carcinoma.
PG  - 3416-3425
LID - 10.21037/tcr-19-2246 [doi]
AB  - BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is one of the most prevalent 
      cancers in renal cancer patients. Currently, mTOR and vascular endothelial growth 
      factor (VEGF) inhibitors are the main targets of clinical drugs used to treat 
      ccRCC. However, the major clinical challenge with these treatments is drug 
      resistance. So far, the mechanisms of drug resistance in cancer are not fully 
      understood. METHODS: We applied tumor-derived exosomes to treat renal cells to 
      detect the survival rate after co-treated with anti-tumor drugs-TNFalpha, mammalian 
      target of rapamycin (mTOR) inhibitor or STAT3 inhibitor. Meanwhile, we also 
      detected the expression change in the protein level related to the proliferation 
      and exosome secretion. RESULTS: Exosomes derived from renal carcinoma cells 
      facilitate resistance in tumors cells when given drug therapy via the 
      mTOR-ERK-STAT-NF-kappaB signaling pathway. CONCLUSIONS: Our results provide new 
      insights on tumor cells resistance to drug therapies in general, and that 
      exosomes could be the potential targets in treatment of ccRCC in future clinical 
      therapy.
CI  - 2020 Translational Cancer Research. All rights reserved.
FAU - Wang, Xiaogang
AU  - Wang X
AD  - Department of Urology, The Third Affiliated Hospital of Soochow University, 
      Changzhou 213000, China.
FAU - Shi, Qianqian
AU  - Shi Q
AD  - Department of Urology, The Third Affiliated Hospital of Soochow University, 
      Changzhou 213000, China.
FAU - Cui, Li
AU  - Cui L
AD  - Department of Urology, The Third Affiliated Hospital of Soochow University, 
      Changzhou 213000, China.
FAU - Wang, Kai
AU  - Wang K
AD  - Department of Urology, The Third Affiliated Hospital of Soochow University, 
      Changzhou 213000, China.
FAU - Gong, Pengfeng
AU  - Gong P
AD  - Department of Urology, The Third Affiliated Hospital of Soochow University, 
      Changzhou 213000, China.
FAU - He, Xiaozhou
AU  - He X
AD  - Department of Urology, The Third Affiliated Hospital of Soochow University, 
      Changzhou 213000, China.
FAU - Xu, Renfang
AU  - Xu R
AD  - Department of Urology, The Third Affiliated Hospital of Soochow University, 
      Changzhou 213000, China.
FAU - Tan, Mingdian
AU  - Tan M
AD  - Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of 
      Medicine, Tongji University, Shanghai 200072, China.
AD  - Current Address Program in Metabolic Biology, Nutritional Sciences & Toxicology, 
      University of California, Berkeley, CA, USA.
FAU - Cao, Yunjie
AU  - Cao Y
AD  - Department of Urology, The Third Affiliated Hospital of Soochow University, 
      Changzhou 213000, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC8798292
OTO - NOTNLM
OT  - Exosomes
OT  - clear cell renal cell carcinoma (ccRCC)
OT  - drug resistance
OT  - mammalian target of rapamycin (mTOR)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tcr-19-2246). The authors have no 
      conflicts of interest to declare.
EDAT- 2020/05/01 00:00
MHDA- 2020/05/01 00:01
PMCR- 2020/05/01
CRDT- 2022/02/04 05:51
PHST- 2019/10/21 00:00 [received]
PHST- 2020/03/03 00:00 [accepted]
PHST- 2022/02/04 05:51 [entrez]
PHST- 2020/05/01 00:00 [pubmed]
PHST- 2020/05/01 00:01 [medline]
PHST- 2020/05/01 00:00 [pmc-release]
AID - tcr-09-05-3416 [pii]
AID - 10.21037/tcr-19-2246 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2020 May;9(5):3416-3425. doi: 10.21037/tcr-19-2246.